<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>ABSTRACT We investigated whether early lymphocyte recovery, after unmanipulated, haploidentical, blood and marrow transplantation (HBMT), affected clinical outcomes in 78 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> evolving from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Lymphocyte recovery was based on the absolute lymphocyte count on day 30 (ALC-30) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients with high ALC-30 (≥ 300 cells/μL) had lower relapse rates (13.8% vs. 35.5%, P=0.049) and lower incidence of <z:mp ids='MP_0001794'>bacterial</z:mp> <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> (3.4% vs. 25.8%, P=0.015) than those with low ALC-30 values </plain></SENT>
<SENT sid="3" pm="."><plain>Multivariate analysis showed that a high ALC-30 was associated with improved overall survival (OS, Hazard Ratio [HR]:0.099, 95% confidence interval [95%CI]:0.029-0.337; P&lt;0.0001), improved <z:hpo ids='HP_0001909'>leukemia</z:hpo>-free survival (HR:0.271, 95%CI:0.122-0.602; P&lt;0.0001), lower relapse rate (HR:0.096, 95%CI:0.011-0.827; P=0.033), and lower transplant-related mortality (TRM, HR:0.073, 95%CI:0.016-0.324; P=0.001) </plain></SENT>
<SENT sid="4" pm="."><plain>Combinations of three mismatches in the human leukocyte antigen loci were associated with a higher TRM (HR:5.026, 95%CI:1.392-18.173; P=0.014) </plain></SENT>
<SENT sid="5" pm="."><plain>Our results suggested that the ALC-30 could predict a favorable OS after unmanipulated HBMT </plain></SENT>
</text></document>